News

Eligible candidates should apply by October 15, 2023, and one candidate will match in March 2024.

Efficacy of 1% colloidal oatmeal cream was similar to prescription barrier cream in treating mild to moderate atopic dermatitis.

A systematic review found that generally, combination therapy has evidence supportive of its efficacy in hidradenitis suppurativa.

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

Today is National Native American Day. Dermatology Times is reviewing the unique dermatologic concerns and disparities faced by members of the Native and Indigenous communities.

Research has shown that biosimilars are highly similar to their originator product in terms of safety and efficacy.

Full clearance of recalcitrant warts was achieved in 68.6% of patients.

Share your insights ahead of October's National Eczema Awareness Month by emailing our team at [email protected].

Yale School of Medicine researchers found tetracycline-class antibiotics were the most prescribed acne treatment for adult female patients between 2002 and 2016.

Public health/public policy researcher and New York Times best-selling author Marty Makary, MD, MPH, FACS, discusses the role of physician-led legislative advocacy in health care and dermatology.

While some resistance was noted against azithromycin, clindamycin, and erythromycin, they were not statistically significant.

Among the many sessions to be held at the 2023 Science of Skincare Summit in Austin, Texas, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Changes to skin and nerve endings as a result of HS may contribute to peripheral neuropathy.

Multiple microinjections significantly improved signs of aging up to 12 weeks after initial injection.

FDA action is no longer expected in Q3 of 2023.

Prior research has demonstrated an association between religious headwear and traction alopecia.

This week’s collection of the latest dermatologic studies covers dermatologic care for patients with disorders of sex development, stem cell transplantation for vitiligo, switching biologic therapies for psoriasis, and combination therapy for hidradenitis suppurativa.

Peter Lio, MD, offers perspectives on topical steroid withdrawal, also known as red skin syndrome or topical steroid addiction.

In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

There may be delays in diagnosis and treatment of psoriasis in patients with darker skin tones due to the clinical presentation variations and less visible erythema.

In this week’s Pointers With Portela, the 208SkinDoc discusses 5 key takeaways about Ozempic, including adverse effects and hidden risks.

Natural and synthetic antimicrobial peptides can penetrate deeper skin layers.

Specific dermoscopic features help determine a diagnosis and the severity of disease.

Investigators found a steady reduction of IgE levels in patients regardless of dupilumab dosing interval.

Roflumilast cream .05% for mild to moderate atopic dermatitis in children also met secondary endpoints.

Mona Shahriari, MD, introduces "Psoriasis Gaps in Care," a special section of the Dermatology Times September print issue dedicated to skin of color research in psoriasis.

Clinicians can use culturally competent care to ease patients’ concerns with identity and better understand the emotional toll of the condition.

The study is the only large-scale dermatologic study to prospectively generate insights into skin conditions among patients of racial and ethnic minority groups.

A study found that 193 proteins were differentially expressed after nemolizumab treatment.

The Small Business Innovation Research grant enables ResVita Bio to develop RVB-101 for treatment of severe atopic dermatitis.